Physician profile
Nanyoung Park
NPI 1043633084
$8,882.21
in general payments reported to CMS, 2019-2025
64 companies · $2,410 in 2025
The $2,410 reported for 2025 was more than what 93% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $572 · 2022: $1,334 · 2023: $2,205 · 2024: $2,361 · 2025: $2,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,881 · Education: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,881.30 |
| Education | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $655.46 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals Lp | $611.69 | 2021-2025 | Lynparza, Enhertu, Calquence |
| Janssen Biotech, INC. | $609.28 | 2021-2025 | Darzalex, Talvey, Rybrevant |
| Novartis Pharmaceuticals Corporation | $553.80 | 2022-2025 | |
| Celgene Corporation | $494.15 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $423.71 | 2021-2023 | Adcetris, Tukysa, Padcev |
| Daiichi Sankyo INC. | $422.66 | 2021-2025 | Enhertu, Datroway |
| Pfizer INC. | $414.67 | 2021-2025 | |
| Genentech USA, INC. | $296.39 | 2021-2025 | Polivy, Tecentriq, Alecensa |
| Eisai INC. | $244.32 | 2022-2025 | |
| Glaxosmithkline, LLC. | $242.54 | 2021-2025 | Ojjaara, Jemperli, Shingrix |
| Abbvie INC. | $242.50 | 2023-2025 | |
| Astellas Pharma US INC | $205.76 | 2022-2025 | Padcev, Xtandi, Vyloy |
| Amgen INC. | $179.16 | 2021-2023 | Lumakras, Kyprolis, Xgeva |
| Incyte Corporation | $171.84 | 2021-2025 | Jakafi, Zynyz, Monjuvi |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $148.61 | 2025 | Brukinsa, Tevimbra |
| Stemline Therapeutics INC. | $140.72 | 2023-2025 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $138.45 | 2021-2024 | Opdivo |
| Deciphera Pharmaceuticals INC. | $136.45 | 2023-2025 | Qinlock, Tgct, Romvimza |
| Ipsen Biopharmaceuticals, INC | $135.88 | 2023-2025 | Onivyde |
| Takeda Pharmaceuticals U.S.A., INC. | $129.83 | 2024-2025 | Iclusig, Fruzaqla, Ninlaro |
| Beigene USA, INC. | $126.73 | 2022-2024 | Brukinsa |
| Coherus Oncology, INC. | $123.27 | 2022-2025 | Loqtorzi |
| Karyopharm Therapeutics INC. | $109.40 | 2023-2025 | Xpovio |
| Novo Nordisk INC | $107.06 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $105.47 | 2022-2023 | Epkinly, Imbruvica |
| Adc Therapeutics America, INC. | $99.01 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.07 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $88.52 | 2021-2024 | Ultomiris |
| Exelixis INC. | $78.03 | 2022-2024 | Cabometyx |
| Sobi, INC | $77.31 | 2023-2025 | |
| Dendreon Pharmaceuticals LLC | $76.96 | 2023-2024 | Provenge |
| Foundation Medicine, INC. | $68.67 | 2022-2023 | Foundationone Cdx |
| Puma Biotechnology, INC. | $67.13 | 2023-2025 | Nerlynx |
| Genzyme Corporation | $65.58 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $62.73 | 2021-2023 | Libtayo |
| Gilead Sciences, INC. | $59.64 | 2022-2024 | |
| Aveo Pharmaceuticals, INC. | $56.94 | 2024-2025 | |
| Tempus Ai, INC | $56.85 | 2025 | Xt Cdx |
| Jazz Pharmaceuticals INC. | $56.29 | 2023-2024 | |
| Servier Pharmaceuticals LLC | $54.42 | 2024 | |
| Mirati Therapeutics, INC. | $51.81 | 2023-2024 | Krazati |
| Array Biopharma INC | $45.81 | 2021-2025 | Tukysa, Mektovi, Braftovi |
| Adaptive Biotechnologies Corporation | $43.48 | 2025 | Clonoseq |
| Janssen Pharmaceuticals, INC | $42.93 | 2023-2025 | Xarelto, Erleada |
| Caris Mpi, INC. | $40.65 | 2025 | Mi Cancer Seek |
| Lilly USA, LLC | $38.46 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Tersera Therapeutics LLC | $38.14 | 2021-2024 | Zoladex |
| Blueprint Medicines Corporation | $37.46 | 2025 | Ayvakit |
| Sun Pharmaceutical Industries INC. | $32.70 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.24 | 2023 | Gilotrif |
| Inari Medical, INC. | $30.12 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Alnylam Pharmaceuticals INC. | $26.81 | 2025 | Givlaari |
| G1 Therapeutics, INC. | $21.79 | 2023 | Cosela |
| Myovant Sciences INC. | $21.64 | 2021 | |
| Ferring Pharmaceuticals INC. | $20.19 | 2024 | Adstiladrin |
| Immunogen, INC. | $19.36 | 2023 | Elahere |
| Exact Sciences Corporation | $18.45 | 2024 | Cologuard Collection Kit |
| Dova Pharmaceuticals | $17.04 | 2021 | |
| Morphosys, US INC. | $16.14 | 2022 | |
| Myriad Genetic Laboratories, INC. | $15.71 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.11 | 2025 | Zoryve |
| Shield Therapeutics INC | $14.80 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $13.42 | 2023 | Akynzeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nanyoung Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.